Nereus Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 675763, Rancho Santa Fe, Californ...Phone Number
(858) 587-4090Website
www.nereuspharm.comRevenue
$7.6 MillionIndustry
About Nereus Pharmaceuticals
Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, Nereus has two oncology drug candidates in clinical trials. NPI-2358, a novel vascular disrupting agent, is being evaluated in patients with solid tumors and lymphomas. The second-generation proteasome inhibitor NPI-0052 is being evaluated in patients with solid tumors, lymphomas, leukemias and multiple myeloma. The company's discovery portfolio includes potential drug candidates for cancer, infectious diseases and inflammation.Explore more
Nereus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Nereus Pharmaceuticals
Compare insights from companies similar to Nereus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nereus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, Nereus has two oncology drug candidates in clinical trials. NPI-2358, a novel vascular disrupting agent, is being evaluated in patients wi... Read More
